CN-120478316-B - Application of alder ketone in preparing medicament for preventing and/or treating ulcerative colitis

Abstract

The invention provides an application of alder ketone in preparing a medicament for preventing and/or treating ulcerative colitis, belongs to the technical field of traditional Chinese medicines, and discovers that the alder ketone can obviously reduce secretion of inflammatory factor IL-8 of intestinal epithelial cells and has an anti-inflammatory effect. The alder ketone is applied to clinical treatment and has the advantages of high efficiency, low toxicity and economical feasibility.

Inventors

• WENG YIJIE
• ZHOU YU
• ZHANG GUIXIA
• CAI YUEQING
• Huang Jiana
• CHEN CHANGAN
• YE SHICAI
• CHEN XINTIAN
• QUAN JUANHUA
• CUI LIJIAO
• YU CAIYUAN

Assignees

• 广东医科大学附属医院

Dates

Publication Date

20260508

Application Date

20250628

Claims (3)

1. 1. Use of alder ketone in the preparation of a medicament for the prevention and/or treatment of ulcerative colitis.
2. 2. Use according to claim 1, characterized in that the aldarone is used in a dose of 10-50 mg/kg.
3. 3. Use according to claim 1, wherein the alder ketone is capable of alleviating weight loss, occult blood and colonic shortening caused by ulcerative colitis.

Description

Application of alder ketone in preparing medicament for preventing and/or treating ulcerative colitis Technical Field The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of alder ketone in preparation of a medicine for preventing and/or treating ulcerative colitis. Background The existing common medicines for clinically treating Ulcerative Colitis (UC) mainly comprise aminosalicylic acid, immunosuppressant, steroid, some biological agents and the like, and the medicines can relieve the illness state to a certain extent, however, the medicines cannot realize complete repair of the mucous membrane barrier function at the present stage, the curative effect is unsatisfactory, the price is generally high, a large amount of medical resources are consumed for long-term maintenance of the medicines, and a plurality of adverse reactions are also caused. Aminosalicylic acid drugs (such as mesalamine) are the preferred drugs, but have limited effects on moderately severe patients. Partial patients have insufficient local concentration due to intestinal flora metabolic difference or uneven drug distribution, and the curative effect is affected. The glucocorticoid can easily cause side effects such as osteoporosis, metabolic disorder and the like after long-term use, and partial patients have hormone resistance or dependence, and the recurrence rate is high after stopping the drug. Immunosuppressant drugs such as azathioprine and cyclosporine may cause bone marrow suppression, hepatorenal toxicity and opportunistic infections. In addition, the biological preparation is expensive, and needs to be used for a long time, thus increasing the economic burden of patients. Aiming at the refractory disease of ulcerative colitis (Ulcerative Colitis, UC), which is the course of the disease is prolonged and easy to recur, the traditional Chinese medicine treatment has remarkable characteristics in the aspects of regulating the whole body function and reducing the recurrence rate. The current clinical urgent need is that the novel traditional Chinese medicine preparation with definite curative effect, high safety and economic applicability has double values for improving the life quality of patients, reducing the medical burden and promoting the modern development of traditional Chinese medicines. Therefore, the searching and developing of the traditional Chinese medicine with good curative effect, small side effect, high safety and low cost has important significance for UC patients, and is beneficial to the development and progress of the promotion of traditional Chinese medicine industry. Disclosure of Invention In view of the above, the invention aims to provide an application of alder ketone in preparing a medicament for preventing and/or treating ulcerative colitis, and researches show that alder ketone is a traditional Chinese medicine component which has wide sources, low price, small toxic and side effects after long-term administration and can effectively treat ulcerative colitis. The invention provides an application of alder ketone in preparing a medicament for preventing and/or treating ulcerative colitis. Preferably, the dosage of the alder ketone is 10-50 mg/kg. Preferably, the alder ketone is capable of alleviating weight loss, occult blood and colonic shortening caused by ulcerative colitis. The invention provides an application of alder ketone in preparing an agent for inhibiting expression of inflammatory factors of a human colon adenocarcinoma cell line. Preferably, the human colon adenocarcinoma cell line is the HT-29 cell line. Preferably, the inflammatory factor is IL-8. Preferably, the alder ketone is used at a concentration of 5-50 mug/mL. Compared with the prior art, the invention has the following beneficial effects that the invention provides the application of the alder ketone in preparing the medicines for preventing and/or treating the ulcerative colitis. The research of the invention discovers that the alder ketone can obviously reduce the secretion of intestinal epithelial cell inflammatory factor IL-8 and has an anti-inflammatory effect, and animal experiments show that the alder ketone can reduce the weight loss, the blood-hidden severity degree and the colon shortening of mice caused by ulcerative colitis, and the alder ketone is suggested to have a protective effect on the ulcerative colitis. The alder ketone is applied to clinical treatment and has the advantages of high efficiency, low toxicity and economical feasibility. Drawings FIG. 1 is a graph showing the effect of TNF- α stimulation of HT-29 cells on the expression of the cytokine IL-8; FIG. 2 shows the inhibition of IL-8 by various concentrations Alnustone; FIG. 3 shows the effect of aldanone on mice model for ulcerative colitis, wherein A is weight loss in mice with reduced aldanone, B is the severity of reduced occult blood in aldanone, and C is the reduction of colon i